BioXcel Therapeutics receives USPTO allowance for key IGALMI patent expiring 2043

BioXcel Therapeutics, Inc.

USPTO allowed U.S. Patent Application No. 18/600,419 for single-dose oromucosal dexmedetomidine up to 120 mcg.
Claims cover acute agitation treatment in schizophrenia or bipolar disorder with QT prolongation <6 microseconds.
Allowed claims mirror the recommended IGALMI dosing regime for that patient subpopulation.
This will be the 14th Orange Book-listed patent for IGALMI, expiring January 12, 2043 subject to adjustment.
CFO Richard Steinhart signed the 8-K filed July 15, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.